10 completed, 3 active not recruiting, 1 terminated, 1 unknown. 5 Phase 1, 5 Phase 3, 3 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 5 |
| Phase 3 | 5 | Active not recruiting 2, Completed 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 3 | Completed 2, Active not recruiting 1 |
| Not applicable | 1 | Terminated 1 |
Follow Ovarian Brenner Tumor: new trials by email Literature Review of Ovarian Brenner Tumor trials Research Report on Ovarian Brenner Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Adavosertib, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis - Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 124 | 2014-07-21 | 2026-09-10 |
| Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy Acetyl-L-Carnitine Hydrochloride, Placebo, Questionnaire Administration - Fatigue, Malignant Ovarian Mixed Epithelial Tumor | Phase 3 | Withdrawn | Gynecologic Oncology Group | 2012-04-01 | 2014-12-31 | |
| Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer Adjuvant Therapy, Aprepitant, Carboplatin - Nausea and Vomiting, Ovarian Brenner Tumor | Not applicable | Terminated | Gynecologic Oncology Group | 4 | 2011-06-01 | 2018-05-22 |
| TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer TLR8 Agonist VTX-2337, Diagnostic Laboratory Biomarker Analysis, Pharmacological Study - Malignant Ovarian Mixed Epithelial Tumor, Ovarian Brenner Tumor | Phase 1 | Completed | Gynecologic Oncology Group | 20 | 2011-03-01 | 2014-12-25 |
| Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Elesclomol Sodium, Paclitaxel - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 2 | Completed | GOG Foundation | 58 | 2010-12-13 | 2021-10-20 |
| Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Bevacizumab, Carboplatin, Computed Tomography - Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 692 | 2010-09-27 | 2026-05-29 |
| Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Bortezomib, Carboplatin, Laboratory Biomarker Analysis - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 33 | 2010-04-05 | 2019-08-09 |
| Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy Cognitive Assessment, Quality-of-Life Assessment - Cognitive Side Effects of Cancer Therapy, Malignant Ovarian Epithelial Tumor | Completed | Gynecologic Oncology Group | 247 | 2010-04-01 | 2018-04-12 | |
| Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Bevacizumab, Carboplatin, Cisplatin - Fallopian Tube Carcinoma, Fallopian Tube Carcinosarcoma | Phase 1 | Completed | National Cancer Institute (NCI) | 431 | 2009-10-28 | 2021-10-20 |
| A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Urokinase-Derived Peptide A6, Laboratory Biomarker Analysis - Fallopian Tube Carcinoma, Malignant Ovarian Mixed Epithelial Tumor | Phase 2 | Completed | Gynecologic Oncology Group | 31 | 2009-07-01 | 2019-01-15 |
| Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Paclitaxel, Cisplatin - Chemotherapeutic Agent Toxicity, Endometrial Adenocarcinoma | Phase 1 | Completed | Gynecologic Oncology Group | 23 | 2009-02-01 | 2014-12-31 |
| Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Bevacizumab, Carboplatin, Docetaxel - Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 1052 | 2007-12-06 | 2025-12-30 |
| Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Bevacizumab, Carboplatin, Laboratory Biomarker Analysis - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 3 | Completed | National Cancer Institute (NCI) | 1873 | 2005-09-01 | 2019-07-23 |
| Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Clinical Observation, Laboratory Biomarker Analysis, Paclitaxel - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 3 | Unknown | GOG Foundation | 1157 | 2005-03-21 | 2021-09-30 |
| Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer Carboplatin, Paclitaxel Poliglumex, Pharmacological Study - Fallopian Tube Carcinoma, Malignant Ovarian Mixed Epithelial Tumor | Phase 1 | Completed | Gynecologic Oncology Group | 32 | 2003-04-01 | 2015-05-08 |
| Collecting Tumor Samples From Patients With Gynecological Tumors Laboratory Biomarker Analysis - Borderline Ovarian Clear Cell Tumor, Borderline Ovarian Serous Tumor | Completed | Gynecologic Oncology Group | 275 | 1992-06-01 | 2016-10-28 |
Brenner Tumor (16) · Fallopian Tube Neoplasms (16) · Ovarian Neoplasms (14) · Neurotoxicity Syndromes (2) · Adenocarcinoma, Clear Cell (1) · Adenocarcinoma, Mucinous (1) · Carcinoma (1) · Dysgerminoma (1) · Fatigue (1) · Gestational Trophoblastic Disease (1) · Melanoma (1) · Mesothelioma, Malignant (1) · Nausea (1) · Neoplasms (1) · Ovarian Germ Cell Cancer (1)
Adnexal Diseases (16) · Endocrine System Diseases (16) · Fallopian Tube Diseases (16) · Female Urogenital Diseases (16) · Female Urogenital Diseases and Pregnancy Complications (16) · Genital Diseases (16) · Genital Diseases, Female (16) · Genital Neoplasms, Female (16) · Gonadal Disorders (16) · Neoplasms by Histologic Type (16) · Neoplasms by Site (16) · Neoplasms, Connective Tissue (16) · Neoplasms, Connective and Soft Tissue (16) · Neoplasms, Fibroepithelial (16) · Neoplasms, Fibrous Tissue (16)
Paclitaxel (8) · Taxes (8) · Carboplatin (7) · Bevacizumab (4) · Disulfides (4) · Immunoglobulin G (4) · Cisplatin (3) · 1,2-diaminocyclohexaneplatinum II citrate (2) · Gemcitabine (2) · Platinum (2) · paclitaxel poliglumex (2) · Aprepitant (1) · Bortezomib (1) · Calcium Dobesilate (1) · Chemotherapy, Adjuvant (1)
Gynecologic Oncology Group (8) · National Cancer Institute (NCI) (6) · GOG Foundation (2)
United States (15) · Canada (3) · South Korea (3) · Japan (2) · Singapore (1)
Don Dizon (2) · Amit M Oza (1) · Bradley J Monk (1) · Bradley Monk (1) · David Kushner (1) · John K Chan (1) · Katherine M Bell-McGuinn (1) · Larry J Copeland (1) · Lisa Hess (1) · Mark Morgan (1) · Michael Cibull (1) · Michael Gold (1) · Robert Burger (1) · Robert L Coleman (1) · Steven Plaxe (1)
PMID 37185961, PMID 21941283, PMID 22204724, PMID 23219660, PMID 26487588, PMID 26933849, PMID 28341300, PMID 28438473, PMID 29550184, PMID 30309721, PMID 31216226, PMID 31708167, PMID 31722153, PMID 33485453, PMID 33610319, PMID 35144591, PMID 35759733, PMID 36252167
U10CA027469 (11), U10CA180868 (8), U10CA101165 (3), N01CM00032 (1), N01CM00038 (1), N01CM00071 (1), U10CA180821 (1), UM1CA186644 (1), UM1CA186705 (1)